VACCINE THERAPY AND/OR GM-CSF IN LOCALLY ADVANCED OR METASTATIC MELANOMA

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。疫苗可以使身体产生免疫反应来杀死肿瘤细胞。集落刺激因子，如沙格拉莫stim，可增加骨髓或外周血中免疫细胞的数量。目前尚不清楚哪种治疗方案对黑色素瘤更有效。这项随机III期试验正在研究肽疫苗疗法和/或sargramostim，并比较它们在治疗局部晚期或转移性黑色素瘤患者中的效果。由于目前尚不清楚这些治疗方法是否对手术治愈的黑色素瘤患者有效，但这些患者仍有很高的疾病复发风险，因此本研究采用安慰剂对照。因此，一些患者将接受实验性治疗，而一些患者将接受安慰剂。将对这些治疗方法进行比较，看看这些治疗方法是否能帮助黑色素瘤患者活得更长，或者在黑色素瘤复发之前有更长的时间。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. It is not yet known which treatment regimen is more effective for melanoma. This randomized Phase III trial is studying peptide vaccine therapy and/or sargramostim and comparing how well they work in treating patients with locally advanced or metastatic melanoma. Since it is not known if any of these treatments are effective for melanoma patients who have been surgically rendered free of disease, but who remain at very high risk for disease recurrence, this study is placebo controlled. Thus, some patients will receive the experimental treatment and some patients will receive a placebo. The treatments will be compared to see if any of these treatments help melanoma patients live longer or have a longer time before the melanoma recurs.